[Federal Register Volume 79, Number 204 (Wednesday, October 22, 2014)]
[Notices]
[Pages 63219-63220]
[FR Doc No: 2014-25128]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Motor Carrier Safety Administration

[FMCSA Docket No. FMCSA-2014-0020]

Qualification of Drivers; Exemption Applications; Diabetes
Mellitus

AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.

ACTION: Notice of final disposition.

-----------------------------------------------------------------------

SUMMARY: FMCSA confirms its decision to exempt 46 individuals from its
rule prohibiting persons with insulin-treated diabetes mellitus (ITDM)
from operating commercial motor vehicles (CMVs) in interstate commerce.
The exemptions enable these individuals to operate CMVs in interstate
commerce.

DATES: The exemptions were effective on August 14, 2014. The exemptions
expire on September 15, 2016.

FOR FURTHER INFORMATION CONTACT: Elaine M. Papp, R.N., Chief, Medical
Programs Division,<PHONE_NUMBER><EMAIL_ADDRESS>FMCSA, Room
W64-224, Department of Transportation, 1200 New Jersey Avenue SE.,
Washington, DC 20590-0001. Office hours are from 8:30 a.m. to 5 p.m.,
Monday through Friday, except Federal holidays.

SUPPLEMENTARY INFORMATION:

I. Electronic Access

    You may see all the comments online through the Federal Document
Management System (FDMS) at: http://www.regulations.gov.
    Docket: For access to the docket to read background documents or
comments, go to http://www.regulations.gov and/or Room W12-140 on the
ground level of the West Building, 1200 New Jersey Avenue SE.,
Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday,
except Federal holidays.
    Privacy Act: Anyone may search the electronic form of all comments
received into any of DOT's dockets by the name of the individual
submitting the comment (or of the person signing the comment, if
submitted on behalf of an association, business, labor union, or other
entity). You may review DOT's Privacy Act Statement for the Federal
Docket Management System (FDMS) published in the Federal Register on
January 17, 2008 (73 FR 3316).

II. Background

    On August 14, 2014, FMCSA published a notice of receipt of Federal
diabetes exemption applications from 46 individuals and requested
comments from the public (79 FR 47711). The public comment period
closed on September 15, 2014, and no comments were received.
    FMCSA has evaluated the eligibility of the 46 applicants and
determined that granting the exemptions to these individuals would
achieve a level of safety equivalent to or greater than the level that
would be achieved by complying with the current regulation 49 CFR
391.41(b)(3).

III. Diabetes Mellitus and Driving Experience of the Applicants

    The Agency established the current requirement for diabetes in 1970
because several risk studies indicated that drivers with diabetes had a
higher rate of crash involvement than the general population. The
diabetes rule provides that ``A person is physically qualified to drive
a commercial motor vehicle if that person has no established medical
history or clinical diagnosis of diabetes mellitus currently requiring
insulin for control'' (49 CFR 391.41(b)(3)).
    FMCSA established its diabetes exemption program, based on the
Agency's July 2000 study entitled ``A Report to Congress on the
Feasibility of a Program to Qualify Individuals with Insulin-Treated
Diabetes Mellitus to Operate in Interstate Commerce as Directed by the
Transportation Act for the 21st Century.'' The report concluded that a
safe and practicable protocol to allow some drivers with ITDM to
operate CMVs is feasible. The September 3, 2003 (68 FR 52441), Federal
Register notice in conjunction with the November 8, 2005 (70 FR 67777),
Federal Register notice provides the current protocol for allowing such
drivers to operate CMVs in interstate commerce.
    These 46 applicants have had ITDM over a range of 1 to 43 years.
These applicants report no severe hypoglycemic reactions resulting in
loss of consciousness or seizure, requiring the assistance of another
person, or resulting in impaired cognitive function that occurred
without warning symptoms, in the past 12 months and no recurrent (2 or
more) severe hypoglycemic episodes in the past 5 years. In each case,
an endocrinologist verified that the driver has demonstrated a
willingness to properly monitor and manage his/her diabetes mellitus,
received education related to diabetes management, and is on a stable
insulin regimen. These drivers report no other disqualifying
conditions, including diabetes-related complications. Each meets the
vision requirement at 49 CFR 391.41(b)(10).
    The qualifications and medical condition of each applicant were
stated and discussed in detail in the August 14, 2014, Federal Register
notice and they will not be repeated in this notice.

IV. Discussion of Comments

    FMCSA received no comments in this proceeding.

V. Basis for Exemption Determination

    Under 49 U.S.C. 31136(e) and 31315, FMCSA may grant an exemption
from the diabetes requirement in 49 CFR 391.41(b)(3) if the exemption
is likely to achieve an equivalent or greater level of safety than
would be achieved without the exemption. The exemption allows the
applicants to operate CMVs in interstate commerce.
    To evaluate the effect of these exemptions on safety, FMCSA
considered medical reports about the applicants' ITDM and vision, and
reviewed the treating endocrinologists' medical opinion related to the
ability of the driver to safely operate a CMV while using insulin.
    Consequently, FMCSA finds that in each case exempting these
applicants from the diabetes requirement in 49 CFR 391.41(b)(3) is
likely to achieve a level of safety equal to that existing without the
exemption.

VI. Conditions and Requirements

    The terms and conditions of the exemption will be provided to the
applicants in the exemption document and they include the following:
(1) That each individual submit a quarterly monitoring checklist
completed by the treating endocrinologist as well as an annual
checklist with a comprehensive medical evaluation; (2) that each
individual reports within 2 business days of occurrence, all episodes
of severe hypoglycemia, significant complications, or inability to
manage diabetes; also, any involvement in an accident or any other
adverse event in a CMV or personal vehicle, whether or not it is
related to an episode of hypoglycemia; (3) that each individual provide
a copy of the ophthalmologist's or optometrist's report to the medical
examiner at the time of the annual medical examination; and (4) that
each individual provide a copy of the annual medical certification to
the employer for retention in the driver's qualification file, or keep
a copy in his/her driver's qualification file if he/she is self-
employed. The driver must also have a copy of the certification when
driving, for presentation to a duly authorized Federal, State, or local
enforcement official.

VII. Conclusion

    Based upon its evaluation of the 46 exemption applications, FMCSA
exempts the following drivers from the diabetes requirement in 49 CFR
391.41(b)(10), subject to the requirements cited above 949 CFR
391.64(b)):

James M. Brooks (VA)
Gary L. Brown (PA)
Richard E. Campney (IA)
Steven J. Causie (MI)
Wesley A. Chain (TX)
Richard M. Cohen (NJ)
Alex A. Comella (NJ)
Jeffrey R. Courtright (CO)
Dwayne P. Daniels (PA)
James T. Dodge (CO)
Richard D. Domingo (NV)
John J. Dominguez (TX)
Mark S. Duda (PA)
Vernon L. Fulton, Jr. (OR)
Gary W. Giles (TX)
Benny B. Gonzales (TX)
Jerry W. Gott (IA)
James L. Hummel (WA)
Matthew J. Jensen (MN)
Joseph A. Kipus (OH)
Kevin L. Kreakie (OH)
Gerald D. Layton (TX)
Steve F. Levicoff (PA)
Kevin C. Lewis (LA)
Timothy M. Malo (ME)
Paul J. Marshall (UT)
David L. Mc Donald (IL)
Thomas K. Miszler (PA)
Rusty A. Neal (IL)
Jacob B. Newman (GA)
Duke R. Pendergraft (TX)
Timothy K. Price (WV)
Michael C. Prue (ME)
Juan C. Rodriguez-Martinez (CA)
Bradlee R. Saxby (IL)
Barry L. Schwab (MI)
Geoffrey E. Showaker (PA)
Nicholas J. Shultz (IN)
Kevin J. Sparks (ME)
George E. Thompson (NJ)
Dale W. Tucker (VA)
William C. Vickery (NY)
Cheryl L. Weber Gambill (IL)
Robert A. Whitcomb (MA)
Rodney L. Wichman (IL)
Richard D. Wiegartz (IL)

    In accordance with 49 U.S.C. 31136(e) and 31315 each exemption is
valid for two years unless revoked earlier by FMCSA. The exemption will
be revoked if the following occurs: (1) The person fails to comply with
the terms and conditions of the exemption; (2) the exemption has
resulted in a lower level of safety than was maintained before it was
granted; or (3) continuation of the exemption would not be consistent
with the goals and objectives of 49 U.S.C. 31136(e) and 31315. If the
exemption is still effective at the end of the 2-year period, the
person may apply to FMCSA for a renewal under procedures in effect at
that time.

    Issued on: October 10, 2014.
 Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2014-25128 Filed 10-21-14; 8:45 am]
BILLING CODE 4910-EX-P


[Federal Register Volume 82, Number 196 (Thursday, October 12, 2017)]
[Rules and Regulations]
[Page 47397]
[FR Doc No: 2017-21931]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[EPA-R04-OAR-2017-0174; FRL-9969-25--Region 4]

Air Plan Approval: Alabama; Transportation Conformity

AGENCY: Environmental Protection Agency (EPA).

ACTION: Withdrawal of direct final rule.

-----------------------------------------------------------------------

SUMMARY: Due to the receipt of an adverse comment, the Environmental
Protection Agency (EPA) is withdrawing the August 17, 2017, direct
final rule that approves an Alabama state implementation plan (SIP)
revision related to transportation conformity requirements. EPA will
address the comment in a subsequent final action based upon the
proposed rulemaking action, also published on August 17, 2017. EPA will
not institute a second comment period on this action.

DATES: The direct final rule published at 82 FR 30935, on August 17,
2017, is withdrawn effective October 12, 2017.

FOR FURTHER INFORMATION CONTACT: Kelly Sheckler, Air Regulatory
Management Section, Air Planning and Implementation Branch, Air,
Pesticides and Toxics Management Division, U.S. Environmental
Protection Agency, Region 4, 61 Forsyth Street SW., Atlanta, Georgia
30303-8960. The telephone number is<PHONE_NUMBER>. Ms. Sheckler can
also be reached via electronic mail at<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: On August 17, 2017 (82 FR 39035), EPA
published a direct final rule approving a SIP revision submitted by the
State of Alabama, through the Alabama Department of Environmental
Management. EPA took a direct final action to approve the portions of
the May 8, 2013, submission that removes specific provisions of Alabama
Administrative Code section 335-3-17-.01, ``Transportation
Conformity,'' from the SIP that are no longer required.
    In the direct final rule, EPA explained that the Agency was
publishing the rule without prior proposal because the Agency viewed
the submittal as a non-controversial SIP amendment and anticipated no
adverse comments. Further, EPA explained that the Agency was publishing
a separate document in the proposed rules section of the Federal
Register to serve as the proposal to approve the SIP revision should an
adverse comment be filed. EPA also noted that the rule would be
effective generally 30 days after the close of the public comment
period, without further notice unless the Agency received adverse
comment by the close of the public comment period. EPA explained that
if the Agency received such comments, then EPA would publish a document
withdrawing the final rule and informing the public that the rule would
not take effect. It was also explained that all public comments
received would then be addressed in a subsequent final rule based on
the proposed rule, and that EPA would not institute a second comment
period on this action.
    EPA received one adverse comment from a single Commenter on the
aforementioned rule. As a result of the comment received, EPA is
withdrawing the direct final rule approving the aforementioned changes
to the Alabama SIPs. EPA will address the comment in a separate final
action based on the proposed action also published on August 17, 2017
(82 FR 39078). EPA will not open a second comment period for this
action.

List of Subjects in 40 CFR Part 52

    Environmental protection, Air pollution control, Incorporation by
reference, Intergovernmental relations, Particulate matter, Reporting
and recordkeeping requirements.

    Dated: September 29, 2017.
Onis ``Trey'' Glen, III
Regional Administrator, Region 4.

PART 52--APPROVAL AND PROMULGATION OF IMPLEMENTATION PLANS

0
Accordingly, the amendment to 40 CFR 52.50(c) published on August 17,
2017 (82 FR 39035), is withdrawn effective October 12, 2017.

[FR Doc. 2017-21931 Filed 10-11-17; 8:45 am]
 BILLING CODE 6560-50-P


[Federal Register Volume 85, Number 22 (Monday, February 3, 2020)]
[Notices]
[Pages 5957-5958]
[FR Doc No: 2020-01935]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPP-2017-0751; FRL-10004-39]

Pesticide Registration Review; Interim Decision for Glyphosate;
Notice of Availability

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice announces the availability of EPA's interim
registration review decision for glyphosate. Registration review is
EPA's periodic review of pesticide registrations to ensure that each
pesticide continues to satisfy the statutory standard for registration,
that is, that the pesticide can perform its intended function without
unreasonable adverse effects on human health or the environment.
Through this program, EPA is ensuring that each pesticide's
registration is based on current scientific and other knowledge,
including its effects on human health and the environment.

FOR FURTHER INFORMATION CONTACT: For pesticide specific information:
Contact the glyphosate registration review email address and phone
number identified in Unit IV.
    For general information on the registration review program,
contact: Melanie Biscoe, Pesticide Re-Evaluation Division (7508P),
Office of Pesticide Programs, Environmental Protection Agency, 1200
Pennsylvania Ave. NW, Washington, DC 20460-0001; telephone number:
(703) 305-7106; email address<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this action apply to me?

    This action is directed to the public in general and may be of
interest to a wide range of stakeholders including environmental, human
health, farm worker, and agricultural advocates; the chemical industry;
pesticide users; and members of the public interested in the sale,
distribution, or use of pesticides. Since others also may be
interested, the Agency has not attempted to describe all the specific
entities that may be affected by this action. If you have any questions
regarding the applicability of this action to a particular entity,
contact the glyphosate registration review email address and phone
number identified in the Table in Unit IV.

B. How can I access the docket?

    The docket for this action, identified by docket identification
(ID) number EPA-HQ-OPP-2017-0751, is available at http://www.regulations.gov or at the Office of Pesticide Programs Regulatory
Public Docket (OPP Docket) in the Environmental Protection Agency
Docket Center (EPA/DC), West William Jefferson Clinton Bldg., Rm. 3334,
1301 Constitution Ave. NW, Washington, DC 20460-0001. The Public
Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through
Friday, excluding legal holidays. The telephone number for the Public
Reading Room is<PHONE_NUMBER>, and the telephone number for the OPP
Docket is<PHONE_NUMBER>. Please review the visitor instructions and
additional information about the docket available at http://www.epa.gov/dockets.

II. Background

    Registration review is EPA's periodic review of pesticide
registrations to ensure that each pesticide continues to satisfy the
statutory standard for registration, that is, the pesticide can perform
its intended function without unreasonable adverse effects on human
health or the environment. As part of the registration review process,
the Agency has completed interim decisions for glyphosate. Through this
program, EPA is ensuring that glyphosate's registration is based on
current scientific and other knowledge, including its effects on human
health and the environment.

III. Authority

    EPA is conducting its registration review of glyphosate pursuant to
section 3(g) of the Federal Insecticide, Fungicide, and Rodenticide Act
(FIFRA) and the Procedural Regulations for Registration Review at 40
CFR part 155, subpart C. Section 3(g) of FIFRA provides, among other
things, that the registrations of pesticides are to be reviewed every
15 years. Under FIFRA, a pesticide product may be registered or remain
registered only if it meets the statutory standard for registration
given in FIFRA section 3(c)(5) (7 U.S.C. 136a(c)(5)). When used in
accordance with widespread and commonly recognized practice, the
pesticide product must perform its intended function without
unreasonable adverse effects on the environment; that is, without any
unreasonable risk to man or the environment, or a human dietary risk
from residues that result from the use of a pesticide in or on food.

IV. What action is the Agency taking?

    Pursuant to 40 CFR 155.58, this notice announces the availability
of EPA's interim registration review decision for glyphosate. The
interim registration review decision is supported by rationales
included in the docket identified in Unit I.B.

        Table--Registration Review Interim Decisions Being Issued
------------------------------------------------------------------------
 Registration review case name
            and No.                 Docket ID No.    Contact information
------------------------------------------------------------------------
Glyphosate Case Number 0178....  EPA-HQ-OPP-2009-03  glyphosateregreview
                                  61.                 @epa.gov, 703-347-
                                                      0292.
------------------------------------------------------------------------

    The proposed interim registration review decision for glyphosate
was posted to the docket and the public was invited to submit any
comments or new information. EPA addressed the comments or information
received during the 120-day comment period for the proposed interim
decisions in the discussion for glyphosate. Comments from the 120-day
comment period that were received may or may not have affected the
Agency's interim decision.

Pursuant to 40 CFR 155.58(c), the registration review case docket for
glyphosate will remain open until all actions required in the interim
decision have been completed.
    Background on the registration review program is provided at:
http://www.epa.gov/pesticide-reevaluation.

    Authority: 7 U.S.C. 136 et seq.

    Dated: January 27, 2020.
Mary Reaves,
Acting Director, Pesticide Re-Evaluation Division, Office of Pesticide
Programs.
[FR Doc. 2020-01935 Filed 1-31-20; 8:45 am]
 BILLING CODE 6560-50-P


[Federal Register Volume 77, Number 103 (Tuesday, May 29, 2012)]
[Notices]
[Page 31682]
[FR Doc No: 2012-13015]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[File No. 500-1]

In the Matter of Quintek Technologies, Inc., The Saint James Co.,
Urigen Pharmaceuticals, Inc., Valor Energy Corp., Wherify Wireless,
Inc., and WinWin Gaming, Inc.; Order of Suspension of Trading

May 24, 2012.
    It appears to the Securities and Exchange Commission that there is
a lack of current and accurate information concerning the securities of
Quintek Technologies, Inc. because it has not filed any periodic
reports since the period ended September 30, 2007.
    It appears to the Securities and Exchange Commission that there is
a lack of current and accurate information concerning the securities of
The Saint James Co. because it has not filed any periodic reports since
the period ended September 30, 2009.
    It appears to the Securities and Exchange Commission that there is
a lack of current and accurate information concerning the securities of
Urigen Pharmaceuticals, Inc. because it has not filed any periodic
reports since the period ended March 31, 2010.
    It appears to the Securities and Exchange Commission that there is
a lack of current and accurate information concerning the securities of
Valor Energy Corp. because it has not filed any periodic reports since
the period ended February 28, 2009.
    It appears to the Securities and Exchange Commission that there is
a lack of current and accurate information concerning the securities of
Wherify Wireless, Inc. because it has not filed any periodic reports
since the period ended June 30, 2008.
    It appears to the Securities and Exchange Commission that there is
a lack of current and accurate information concerning the securities of
WinWin Gaming, Inc. because it has not filed any periodic reports since
the period ended June 30, 2006.
    The Commission is of the opinion that the public interest and the
protection of investors require a suspension of trading in the
securities of the above-listed companies.
    Therefore, it is ordered, pursuant to Section 12(k) of the
Securities Exchange Act of 1934, that trading in the securities of the
above-listed companies is suspended for the period from 9:30 a.m. EDT
on May 24, 2012, through 11:59 p.m. EDT on June 7, 2012.

    By the Commission.
Jill M. Peterson,
Assistant Secretary.
[FR Doc. 2012-13015 Filed 5-24-12; 4:15 pm]
BILLING CODE 8011-01-P


[Federal Register Volume 82, Number 182 (Thursday, September 21, 2017)]
[Notices]
[Pages 44187-44188]
[FR Doc No: 2017-20105]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-5255]

Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of
Meeting; Establishment of a Public Docket; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; establishment of a public docket; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) announces a
forthcoming public advisory committee meeting of the Dermatologic and
Ophthalmic Drugs Advisory Committee. The general function of the
committee is to provide advice and recommendations to the Agency on
FDA's regulatory issues. The meeting will be open to the public. FDA is
establishing a docket for public comment on this document.

DATES: The public meeting will be held on October 13, 2017, from 8:30
a.m. to 4 p.m.

ADDRESSES: FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31
Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993-
0002. Answers to commonly asked questions including information
regarding special accommodations due to a disability, visitor parking,
and transportation may be accessed at: https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.
    FDA is establishing a docket for public comment on this meeting.
The docket number is FDA-2017-N-5255. The docket will close on October
12, 2017. Submit either electronic or written comments on this public
meeting by October 12, 2017. Late, untimely filed comments will not be
considered. Electronic comments must be submitted on or before October
12, 2017. The https://www.regulations.gov electronic filing system will
accept comments until midnight Eastern Time at the end of October 12,
2017. Comments received by mail/hand delivery/courier (for written/
paper submissions) will be considered timely if they are postmarked or
the delivery service acceptance receipt is on or before that date.
    Comments received on or before September 28, 2017, will be provided
to the committee. Comments received after that date will be taken into
consideration by the Agency.
    You may submit comments as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2017-N-5255 for ``Dermatologic and Ophthalmic Drugs Advisory
Committee; Notice of Meeting; Establishment of a Public Docket; Request
for Comments.'' Received comments, those filed in a timely manner (see
ADDRESSES), will be placed in the docket and, except for those
submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information

redacted/blacked out, will be available for public viewing and posted
on https://www.regulations.gov. Submit both copies to the Dockets
Management Staff. If you do not wish your name and contact information
to be made publicly available, you can provide this information on the
cover sheet and not in the body of your comments and you must identify
this information as ``confidential.'' Any information marked as
``confidential'' will not be disclosed except in accordance with 21 CFR
10.20 and other applicable disclosure law. For more information about
FDA's posting of comments to public dockets, see 80 FR 56469, September
18, 2015, or access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: LaToya Bonner, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-
796-9001, FAX:<PHONE_NUMBER>, email<EMAIL_ADDRESS>or FDA Advisory
Committee Information Line, 1-800-741-8138<PHONE_NUMBER> in the
Washington, DC area). A notice in the Federal Register about last
minute modifications that impact a previously announced advisory
committee meeting cannot always be published quickly enough to provide
timely notice. Therefore, you should always check the Agency's Web site
at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down
to the appropriate advisory committee meeting link, or call the
advisory committee information line to learn about possible
modifications before coming to the meeting.

SUPPLEMENTARY INFORMATION:
    Agenda: The committee will discuss the safety and efficacy of new
drug application (NDA) 208254, for netarsudil ophthalmic solution
0.02%, submitted by Aerie Pharmaceuticals Inc., for the proposed
indication to reduce elevated intraocular pressure (IOP) in patients
with open-angle glaucoma (OAG) or ocular hypertension (OHT).
    FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting
link.
    Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
All electronic and written submissions submitted to the Docket (see the
ADDRESSES section) on or before September 28, 2017, will be provided to
the committee. Oral presentations from the public will be scheduled
between approximately 1 p.m. and 2 p.m. Those individuals interested in
making formal oral presentations should notify the contact person and
submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation on or before September 20, 2017. Time allotted
for each presentation may be limited. If the number of registrants
requesting to speak is greater than can be reasonably accommodated
during the scheduled open public hearing session, FDA may conduct a
lottery to determine the speakers for the scheduled open public hearing
session. The contact person will notify interested persons regarding
their request to speak by September 21, 2017.
    Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
    FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require special accommodations due to a
disability, please contact LaToya Bonner at least 7 days in advance of
the meeting.
    FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).

    Dated: September 15, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-20105 Filed 9-20-17; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register Volume 87, Number 213 (Friday, November 4, 2022)]
[Notices]
[Pages 66689-66690]
[FR Doc No: 2022-24038]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Combined Notice of Filings #1

    Take notice that the Commission received the following electric
rate filings:

    Docket Numbers: ER10-1580-018.
    Applicants: Saguaro Power Company LP.
    Description: Notice of Non-Material Change in Status of Saguaro
Power Company.
    Filed Date: 10/28/22.
    Accession Number: 20221028-5385.
    Comment Date: 5 p.m. ET 11/18/22.

    Docket Numbers: ER10-1818-032.
    Applicants: Public Service Company of Colorado.
    Description: Notice of Change in Status of Public Service Company
of Colorado.
    Filed Date: 10/28/22.
    Accession Number: 20221028-5322.
    Comment Date: 5 p.m. ET 11/18/22.

    Docket Numbers: ER15-1905-011.
    Applicants: AZ721 LLC.
    Description: Notice of Change in Status of Amazon Energy LLC.
    Filed Date: 10/31/22.
    Accession Number: 20221031-5047.
    Comment Date: 5 p.m. ET 11/21/22.

    Docket Numbers: ER16-1496-001.
    Applicants: Canadian Hills Wind, LLC.
    Description: Compliance filing: Canadian Hills Wind, LLC Notice of
Non-Material Change in Status to be effective 11/1/2022.
    Filed Date: 10/31/22.
    Accession Number: 20221031-5144.
    Comment Date: 5 p.m. ET 11/21/22.

    Docket Numbers: ER17-1217-001.
    Applicants: Total Gas & Power North America, Inc.
    Description: Notice of Non-Material Change in Status of
TotalEnergies Gas & Power North America, Inc., et al.
    Filed Date: 10/28/22.
    Accession Number: 20221028-5384.
    Comment Date: 5 p.m. ET 11/18/22.

    Docket Numbers: ER19-1078-001; ER20-443-001; ER22-611-001.
    Applicants: Wildcat I Energy Storage, LLC, Acorn I Energy Storage,
LLC, PPA Grand Johanna LLC.
    Description: Triennial Market Power Analysis and Notice of Change
of Status for Southwest Region of Acorn I Energy Storage, LLC, et al.
    Filed Date: 10/31/22.
    Accession Number: 20221031-5199.
    Comment Date: 5 p.m. ET 12/30/22.

    Docket Numbers: ER20-1653-001.
    Applicants: Kingfisher Wind, LLC.
    Description: Compliance filing: Kingfisher Wind, LLC Notice of Non-
Material Change in Status to be effective 11/1/2022.
    Filed Date: 10/31/22.
    Accession Number: 20221031-5142.
    Comment Date: 5 p.m. ET 11/21/22.

    Docket Numbers: ER22-2719-001.
    Applicants: PPL Electric Utilities Corporation, PJM
Interconnection, L.L.C.
    Description: Tariff Amendment: PPL Electric Utilities Corporation
submits tariff filing per 35.17(b): PPL Electric submits Response to
Deficiency Letter in ER22-2719 to be effective 10/25/2022.
    Filed Date: 10/31/22.
    Accession Number: 20221031-5092.
    Comment Date: 5 p.m. ET 11/21/22.

    Docket Numbers: ER23-265-001.
    Applicants: Buckeye Power, Inc., PJM Interconnection, L.L.C.
    Description: Tariff Amendment: Buckeye Power, Inc. submits tariff
filing per 35.17(b): Revised SA No. 4753--NITSA Among PJM and Buckeye
Power, Inc. to be effective 10/1/2022.
    Filed Date: 10/31/22.
    Accession Number: 20221031-5080.
    Comment Date: 5 p.m. ET 11/21/22.

    Docket Numbers: ER23-273-000.
    Applicants: Wisconsin Public Service Corporation.
    Description: Sec.  205(d) Rate Filing: Revisions to the AS Tariff
for Reactive Supply Service to be effective 1/1/2023.
    Filed Date: 10/28/22.
    Accession Number: 20221028-5293.

    Comment Date: 5 p.m. ET 11/18/22.

    Docket Numbers: ER23-274-000.
    Applicants: Duke Energy Florida, LLC.
    Description: Sec.  205(d) Rate Filing: DEF-FPL Concurrence SA 391
to be effective 9/28/2022.
    Filed Date: 10/28/22.
    Accession Number: 20221028-5295.
    Comment Date: 5 p.m. ET 11/18/22.

    Docket Numbers: ER23-275-000.
    Applicants: Buckleberry Solar, LLC.
    Description: Sec.  205(d) Rate Filing: MBR Tariff Updates to be
effective 10/31/2022.
    Filed Date: 10/28/22.
    Accession Number: 20221028-5299.
    Comment Date: 5 p.m. ET 11/18/22.

    Docket Numbers: ER23-276-000.
    Applicants: TransAlta Energy Marketing (U.S.) Inc.
    Description: Compliance filing: Notice and Justification for Spot
Sales above WECC Soft Cap to be effective N/A.
    Filed Date: 10/28/22.
    Accession Number: 20221031-5002.
    Comment Date: 5 p.m. ET 11/18/22.

    Docket Numbers: ER23-277-000.
    Applicants: Westlake US 2 LLC.
    Description: Baseline eTariff Filing: Market Based Rate Application
to be effective 1/1/2023.
    Filed Date: 10/31/22.
    Accession Number: 20221031-5006.
    Comment Date: 5 p.m. ET 11/21/22.

    Docket Numbers: ER23-278-000.
    Applicants: Brookfield Renewable Trading and Marketing LP.
    Description: Compliance filing: Notification of Spot Market Sale
Above Soft Cap and Refund Report to be effective N/A.
    Filed Date: 10/31/22.
    Accession Number: 20221031-5039.
    Comment Date: 5 p.m. ET 11/21/22.

    Docket Numbers: ER23-279-000.
    Applicants: Startrans IO, LLC.
    Description: Sec.  205(d) Rate Filing: TRBAA 2023 Update to be
effective 1/1/2023.
    Filed Date: 10/31/22.
    Accession Number: 20221031-5040.
    Comment Date: 5 p.m. ET 11/21/22.

    Docket Numbers: ER23-280-000.
    Applicants: Louisville Gas and Electric Company.
    Description: Sec.  205(d) Rate Filing: Amending the SERTP's List of
Enrollees_Gulf Power Company's Withdrawal from the to be effective 1/1/
2023.
    Filed Date: 10/31/22.
    Accession Number: 20221031-5042.
    Comment Date: 5 p.m. ET 11/21/22.

    Docket Numbers: ER23-281-000.
    Applicants: Midcontinent Independent System Operator, Inc.
    Description: Sec.  205(d) Rate Filing: 2022-10-31_SA 3435 Entergy
Mississippi-Wildwood Solar 1st Rev GIA (J908) to be effective 10/19/
2022.
    Filed Date: 10/31/22.
    Accession Number: 20221031-5044.
    Comment Date: 5 p.m. ET 11/21/22.

    Docket Numbers: ER23-282-000.
    Applicants: Cardinal Point LLC.
    Description: Sec.  205(d) Rate Filing: Notice of Change in Status
to be effective 11/1/2022.
    Filed Date: 10/31/22.
    Accession Number: 20221031-5046.
    Comment Date: 5 p.m. ET 11/21/22.

    Docket Numbers: ER23-283-000.
    Applicants: CP Energy Marketing (US) Inc.
    Description: Sec.  205(d) Rate Filing: Notice of Change in Status
to be effective 11/1/2022.
    Filed Date: 10/31/22.
    Accession Number: 20221031-5048.
    Comment Date: 5 p.m. ET 11/21/22.

    Docket Numbers: ER23-284-000.
    Applicants: Meadowlark Wind I LLC.
    Description: Sec.  205(d) Rate Filing: Notice of Change in Status
to be effective 11/1/2022.
    Filed Date: 10/31/22.
    Accession Number: 20221031-5049.
    Comment Date: 5 p.m. ET 11/21/22.

    Docket Numbers: ER23-285-000.
    Applicants: Alabama Power Company, Georgia Power Company,
Mississippi Power Company.
    Description: Sec.  205(d) Rate Filing: Alabama Power Company
submits tariff filing per 35.13(a)(2)(iii: OATT Amendment Filing
(Exhibit K-9--remove Gulf from SERTP) to be effective 1/1/2023.
    Filed Date: 10/31/22.
    Accession Number: 20221031-5068.
    Comment Date: 5 p.m. ET 11/21/22.

    Docket Numbers: ER23-286-000.
    Applicants: AMP Transmission, LLC, PJM Interconnection, L.L.C.
    Description: Sec.  205(d) Rate Filing: AMP Transmission, LLC
submits tariff filing per 35.13(a)(2)(iii: AMPT Revisions to OATT
Attachments H-32 and H-32C to be effective 1/1/2023.
    Filed Date: 10/31/22.
    Accession Number: 20221031-5071.
    Comment Date: 5 p.m. ET 11/21/22.

    The filings are accessible in the Commission's eLibrary system
(https://elibrary.ferc.gov/idmws/search/fercgensearch.asp) by querying
the docket number.
    Any person desiring to intervene or protest in any of the above
proceedings must file in accordance with Rules 211 and 214 of the
Commission's Regulations (18 CFR 385.211 and 385.214) on or before 5:00
p.m. Eastern time on the specified comment date. Protests may be
considered, but intervention is necessary to become a party to the
proceeding.
    eFiling is encouraged. More detailed information relating to filing
requirements, interventions, protests, service, and qualifying
facilities filings can be found at: http://www.ferc.gov/docs-filing/efiling/filing-req.pdf. For other information, call<PHONE_NUMBER>
(toll free). For TTY, call<PHONE_NUMBER>.

    Dated: October 31, 2022.
Debbie-Anne A. Reese,
Deputy Secretary.
[FR Doc. 2022-24038 Filed 11-3-22; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register: May 28, 2010 (Volume 75, Number 103)]
[Notices]
[Page 30013-30014]
[DOCID:fr28my10-68]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project No. 2088-075]

South Feather Water and Power Agency; Notice of Availability of
Environmental Assessment

May 20, 2010.
    In accordance with the National Environmental Policy Act of 1969,
as amended, and the Federal Energy Regulatory Commission's (Commission)
regulations, (18 CFR Part 380), Commission staff has prepared an
environmental assessment (EA) regarding South Feather Water and Power
Agency's (SFWPA) request to raise the dam crest and modify the spillway
at Sly Creek Dam, part of the Sly Creek development of the South
Feather Power Project (FERC No. 2088). Sly Creek is located on Sly
Creek

Reservoir, which receives water from Lost Creek, and the Slate Creek
and South Fork Feather River diversion tunnels in Butte, Yuba and
Plumas counties, California.
    SFWPA's Proposed Action includes: (1) Raising Sly Creek Dam
approximately 10 feet through the use of mechanically stabilized earth
walls constructed from approximately 20,000 cubic yards of fill from an
onsite borrow area; (2) modifying the spillway crest structure; (3)
replacing the spill gate; and (4) altering roadway approaches to the
Sly Creek Dam crest and re-paving the road to improve drainage
conditions in the adjacent campground and borrow site.
    The EA contains Commission staff's analysis of the potential
environmental effects of the Proposed Action and concludes that the
Proposed Action, with the implementation of environmental protective
measures, would not constitute a major federal action significantly
affecting the quality of the human environment.
    A copy of the EA is available for review at the Commission's Public
Reference Room, or it may be viewed on the Commission's Web site at
http://www.ferc.gov using the ``eLibrary'' link. Enter the docket
number (P-2088) in the docket number field to access the document.
Additional information about the project is available from the
Commission's Web site using the eLibrary link. For assistance with
eLibrary, contact<EMAIL_ADDRESS>or toll-free at (866) 208-
3676; for TTY, contact<PHONE_NUMBER>.

Kimberly D. Bose,
Secretary.
[FR Doc. 2010-12858 Filed 5-27-10; 8:45 am]
BILLING CODE 6717-01-P